SF3B1 and myelodysplastic syndrome: Despite the mutual exclusivity of mutations in spliceosome members, mutations in SF3B1 appear to be markedly high in MDS-RS with an incidence of 60%-80% in these patients, but only 10–20% of unselected MDS.